[PDF] Top 20 Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia
Has 10000 "Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia" found on our website. Below are the top 20 most common "Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia".
Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia
... allows highly specific, rapid and sensi- tive screening for NPM1 ...all mutations were detected and none was missed by this method. In addition, our ... Voir le document complet
5
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
... INTRODUCTION Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disease characterized by accumulation of a variety of somatically acquired genetic aberrations ... Voir le document complet
10
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
... agents for acute myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not easy to establish and manipulate in the ...accessible ... Voir le document complet
8
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy
... of acute myeloid leukemia (AML) to therapeutic agents is ...understood and addressed. In this paper, we demonstrate that inhibition of deubiquitinylase USP7 signi ficantly reduces cell ... Voir le document complet
17
Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
... Dysregulated in IDH1 Mutant Cells We first compared the proteome of IDH1 mutant HL60 cells to the one of IDH1 WT ...1.5 and FDR lower than ...this specific protein set with Genomatix software ... Voir le document complet
19
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
... CRISPR-Cas9 and RNAi experiments targeting UTX/JMJD3, it was demonstrated that sensitivity by GSK-J4 in RUNX1 mut AML cells observed in vitro was most likely due to an off- target effect of ... Voir le document complet
89
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
... intensity in ATRA-treated to vehicle-treated cells ± SEM; n = 5) in HL60 cells parental, control (Cl 14), WT (Cl 2), or with IDH1–R132H mutations (clone 5 or ...enriched in mutant IDH1 HL60 ... Voir le document complet
16
Dexamethasone in hyperleukocytic acute myeloid leukemia
... enrichment in the dexamethasone Figure 4. Activity of dexamethasone against acute myeloid leukemia ...cultured in minimum essential medium alpha whose cytogenetic and molecular ... Voir le document complet
12
Analysis of the proteasome-autophagy crosstalk under proteotoxic stress conditions in acute myeloid leukemia
... Autophagy in cancer Loss of a survival pathway, such as autophagy, undermines ...interpreted in the context of cancer, the autophagy role in cancer, in effect, is ...normal and cancer ... Voir le document complet
222
In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival
... apparent in the Kaplan–Meier curves in AML with recurrent genetic aberrations, in AML, not otherwise specified, in the favorable risk group AML and in AML with normal karyotypes ... Voir le document complet
9
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
... level and assigning all doses below or above to the low or high dose level, ...respectively. For each of these components, we assigned a weighted score of 1 for the lower dose and an extra ... Voir le document complet
12
Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
... patients and those with medical comorbid conditions, several groups of investigators have carried out allo-HCT after reduced intensity (RIC) or truly nonmyeloablative conditioning ...chemo/radiotherapy for ... Voir le document complet
3
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
... observed in stem cell transplantation and its impact in this set- ting has been extensively ...outcome in MMURD transplantation for acute myeloid leukemia (AML) ... Voir le document complet
8
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
... Introduction Acute myeloid leukaemia (AML) is a clonal disorder that affects hematopoietic stem cells or myeloid ...cells in the bone marrow and peripheral blood and leads to ... Voir le document complet
24
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
... trial in hospitalized patients with AML/ high-risk myelodysplastic syndrome to assess the feasibility and tolerance of AFMT in the setting of IC and antibiotic therapy given during ... Voir le document complet
12
en fr Targeting NPM1c in Acute Myeloid leukemia NPM1C, une cible dans le traitement des leucémies aigues myéloides
... ; and Hiba A. El Hajj, PhD 1,5 BACKGROUND: Nucleophosmin 1 (NPM1) is a nucleocytoplasmic shuttling protein mainly localized in the ...nucleolus. NPM1 is frequently mutated in ... Voir le document complet
241
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
... 5% and 10% of GFP- positive cells. Cells were expanded for 48 hours before selection with 1 μg/ml ...pelleted and frozen down to constitute the day 0 time point, and cells were maintained ... Voir le document complet
34
Acute lymphoblastic leukemia in children
... Le nombre (n = 13 soit 16,5 %) d’échecs thé- rapeutiques (rechutes et patients réfractaires : plus de 25 % de blastes après l’induction) que nous avons observé est bas mais le taux de “r[r] ... Voir le document complet
7
Isolated granulocytic sarcoma of the pancreas: A tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia
... action in neoplastic cells ...AML in 3-10% of patients ...AML in patients with myeloproliferative disorders or myelodysplasic syn- drome ...skin and bones [5], with abdominal origin being very ... Voir le document complet
6
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
... MD; and Franc ¸ois-Xavier Mahon, MD, PhD; for the French Chronic Myeloid Leukemia Study Group BACKGROUND: The ultimate goal of chronic myeloid leukemia management in the ... Voir le document complet
8
Sujets connexes